Our mission is to discover and develop innovative therapeutics that preserve and restore brain function for patients at risk for neurodegeneration, to benefit the lives of those patients, their families, and society as a whole.

from http://www.agenebio.com

Research Grants show all

NIH6

Publications show all

AgeneBio has published 1 articles.

Patents show all

29Applications6Issued

SEC Filings show all

D11

Private Funding Events

DateOfferedSoldType
2015-02-06$900,000$400,000Debt, Option to Acquire, Security to be Acquired
2014-10-17$10,000,000$4,113,127Equity
2013-11-18$3,300,000$1,000,113Equity, Option to Acquire, Security to be Acquired
2013-06-04$4,000,000$1,000,000Equity, Option to Acquire, Security to be Acquired
2012-09-25$975,000$450,000Debt, Option to Acquire, Security to be Acquired
2011-12-22$5,000,000$3,688,610Debt, Option to Acquire, Security to be Acquired
2011-05-19$5,000,000$1,396,610Debt, Option to Acquire, Security to be Acquired
2011-01-07$2,000,000$846,610Debt, Option to Acquire
2010-04-12$300,000$300,000Debt, Option to Acquire
2009-07-10Indefinite$50,000Debt, Option to Acquire

Contact Information

    Key Executives

    • Michela Gallagher
      Director, Executive Officer
    • Timothy F. Parshall
      Director, Executive Officer
    • Robert Postlethwait
      Director
    • Brian Stemme
      Director
    • William Ringo
      Director
    • Kristin Sherman
      Executive Officer
    • Gardiner Smith
      Executive Officer, Director
    • James Barrett
      Director
    • Floyd Bloom
      Director
    • Ronald Nordmann
      Director
    • Gerald W. Mclaughlin
      Executive Officer, Director
    • Sharon Rosenzweig-lipson
      Executive Officer
    • Patrick Lepore
      Director
    • Charles Clarvit
      Director